Sensus Healthcare Inc(SRTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:00 PM ET (Korea 10/24 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.94 | Insider Own | 18.67% | Shs Outstand | 16.5M | Perf Week | 6.5% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 85.8% | Insider Trans | 5.95% | Shs Float | 13.4M | Perf Month | 1.37% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.06 | Inst Own | 25.18% | Short Float | 1.7% | Perf Quarter | -2.32% |
| Income | -0.02B | P/S | 2.77 | EPS this Y | -68.62% | Inst Trans | -4.31% | Short Ratio | 7.87 | Perf Half Y | -25.13% |
| Sales | 0.02B | P/B | 1.32 | EPS next 5Y | - | ROA | -30.94% | Short Interest | 0.23M | Perf YTD | -25.88% |
| Book/sh | 2.24 | P/C | 3.2 | EPS past 3/5Y | - -2.6% | ROE | -34.83% | 52W High | -46.27% ($5.49) | Perf Year | -10.33% |
| Cash/sh | 0.92 | P/FCF | - | Sales past 3/5Y | -14.86% 23.47% | ROIC | -41.93% | 52W Low | 10.9% ($2.66) | Perf 3Y | 29.39% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1719.88% | Gross Margin | 36.39% | Volatility(W/M) | 5.07% 4.45% | Perf 5Y | -26.8% |
| Dividend TTM | - | EV/Sales | 1.93 | Sales Y/Y TTM | -53.4% | Oper. Margin | -75.72% | ATR (14) | 0.14 | Perf 10Y | -53.54% |
| Dividend Ex-Date | - | Quick Ratio | 4.3 | EPS Q/Q | -737.01% | Profit Margin | -88.45% | RSI (14) | 51.32 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.71 | Sales Q/Q | -68.69% | SMA20 | 1.47% ($2.91) | Beta | 1.18 | Target Price | $5.38 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/13 | SMA50 | -3.68% ($3.06) | Rel Volume | 0.43 | Prev Close | $2.87 |
| Employees | 60 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -324% -50.23% | SMA200 | -17.76% ($3.59) | Avg Volume(3M) | 0.03M | Price | $2.95 |
| IPO | 2016/7/26 | Option/Short | Yes/Yes | Trades | 141 | Volume | 12,498 | Change | 2.79% |
An innovative medical device company that treats non-melanoma skin cancer and keloid scars using non-invasive low-energy radiation technology (Superficial Radiation Therapy, or SRT). Backed by the newly implemented insurance reimbursement framework in 2026, the company is leading the early diagnosis and treatment optimization of dermatology and oncology markets.
Over the past 1 year, on the lower side
46% below its 1-year high.
Traded less than usual. That is 43% of its average volume.
SRTS has a sound balance sheet but weak earning power
Of every $100 in sales, $75.72 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -68.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $277. Peers typically go for $141. Compared with its own 3-year average, it is 231% pricier now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -26.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 25.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #94 of 142 in the industry
Based on market cap of $49M.
SRTS#94 Sensus Healthcare Inc $49M PER - 
MYO#95 Myomo Inc $48M PER - 
MDAI#96 Spectral AI Inc $46M PER - 
COCH#97 Envoy Medical Inc $46M PER - 
SNWV#98 Sanuwave Health Inc $45M PER 21.7 
FAQ
What kind of company is SRTS?
SRTS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of SRTS?
The market cap of SRTS is approximately $49M, ranking 4,862 within its sector.
What is the 52-week high and low for SRTS?
SRTS has recorded a 52-week high of $5.49 and a low of $2.66.
